Mitochondrial-Inflammatory Axis Dysregulation Triggers Disulfidptosis and the Systemic Repair Mechanism of Bisphenol A Following Spinal Cord Injury

Why It Matters

If translatable to humans, BPA could represent a novel strategy to curb mitochondrial‑driven cell death after spinal cord trauma, addressing a major unmet need in neuro‑rehabilitation.

Key Takeaways

• BPA improves locomotor scores in mouse spinal cord injury model.
• Genes Ndufs1, Ndufa11, Ndufb10 linked to OXPHOS restored by BPA.
• Metabolites LTB4 and PGB2 rise in injury, normalized with BPA.
• Study suggests BPA disrupts mitochondrial‑inflammatory feedback, reducing disulfidptosis.

Pulse Analysis

Spinal cord injury remains a leading cause of permanent disability, affecting millions worldwide and generating billions in healthcare costs. Recent research has highlighted disulfidptosis—a form of regulated cell death triggered by aberrant disulfide stress—as a key contributor to secondary neuronal loss after trauma. This pathway intertwines mitochondrial oxidative phosphorylation failure with a surge of inflammatory mediators, creating a self‑amplifying loop that accelerates tissue degeneration. Understanding how to interrupt this loop is therefore a priority for clinicians and biotech firms seeking to improve functional outcomes for SCI patients.

In the new murine study, investigators administered bisphenol A (BPA), a compound traditionally viewed as an environmental contaminant, to mice with experimentally induced spinal cord lesions. BPA‑treated animals displayed significantly higher scores on the Basso Mouse Scale and more orderly gait patterns compared with untreated controls. Transcriptomic profiling revealed that BPA restored expression of three nuclear‑encoded OXPHOS genes—Ndufs1, Ndufa11, and Ndufb10—while metabolomic data showed normalization of arachidonic‑acid derivatives leukotriene B4 and prostaglandin B2. By rebalancing mitochondrial energy production and dampening inflammatory lipid signaling, BPA appears to suppress the disulfidptosis cascade.

The translational potential of these findings is compelling, yet several hurdles remain. Although BPA demonstrated neuroprotective effects in rodents, its endocrine‑disrupting reputation raises safety concerns that must be addressed through dose‑optimization and analog development. Moreover, the study underscores the broader therapeutic concept of targeting mitochondrial‑inflammatory crosstalk, a strategy that could be extended to other neurodegenerative conditions where disulfidptosis is implicated. Future clinical trials will need to verify efficacy, establish pharmacokinetic profiles, and evaluate long‑term outcomes, but the work opens a promising avenue for drug discovery aimed at mitigating secondary injury after spinal cord trauma.